Presentaciones
Keynote lecture
Session 1 – High-Risk Non-Muscle-Invasive Bladder Cancer
-
BCG monotherapy is here to stay
Dr. José Luis Domínguez, Urology Department, Instituto Valenciano de Oncología, Valencia -
Systemic immunotherapy is the future
Dr. Óscar Rodríguez Faba, Urology Department, Fundació Puigvert, Barcelona -
Other intravesical therapies will be the winners
Dr. Evanguelos Xylinas, Urology Department, Hôpital Bichat Claude-Bernard, Paris, France -
Discussion with a clinical case
Dr. Mario Hernández, Urology Department, Hospital Universitario 12 de Octubre, Madrid
Session 2 – Perioperative treatment in localized muscle-invasive bladder cancer: what should I choose?
-
Multiparametric MRI for clinical decision making, do we really need TURBT?
Dr. Albert Carrión, Urology Department, Hospital Universitari Vall d’Hebron, Barcelona -
Neoadjuvant/perioperative therapy is the best option
Dr. Jose Daniel Subiela, Urology Department, Hospital Universitario 12 de Octubre, Madrid -
Adjuvant therapy (guided by liquid biopsy?) is the best option
Dr. Álvaro Pinto, Medical Oncology Department, Hospital Universitario La Paz, Madrid -
Discussion with a clinical case
Dra. Carmen Gómez del Cañizo, Servicio de Urología, Hospital Universitario 12 de Octubre, Madrid -
Bonus track – Bladder sparing options: past, present and future
Dr. Félix Guerrero, Urology Department, Hospital Universitario 12 de Octubre, Madrid
Session 3 – Metastatic urothelial carcinoma: the current landscape
-
How do these treatments impact subsequent lines of therapy?
Dr. Patrizia Giannatempo, Instituto Nazionale dei Tumori, Milán (Italia) -
Discussion with a clinical case
Dr. Jorge Esteban, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid -
Bonus track – New molecules and mechanisms of action in preclinical development
Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander